The biopharmaceutical industry remains enthusiastic about adopting AI. With overstretched healthcare systems, soaring drug research and development (R&D) costs, and increasing challenges in matching supply to demand, AI could offer biomanufacturing considerable benefits.
Using machine learning to identify the best targets and design a corresponding compound offers the opportunity to vastly speed up pipelines. It's an appealing concept when considering R&D takes an average of 17 months to conduct. And the more AI drug discovery platforms are utilized, the better they will become. They built algorithms that are so smart, they just keep getting smarter with each iteration.
And just as the company uses AI to simulate an enzyme’s mode of action, digital twins can allow the virtual duplication of complex biomanufacturing processes before they are physically carried out. That can save manufacturers both time and money by performing virtual experiments before production. If widely implemented, AI could lead to faster production times with higher yields and improved product quality.
【MORE】